Jiu-rong Li1, Wei-xun Zhou2, Ke-wu Huang3, Yang Jin4, Jin-ming Gao1. 1. Department of Respiratory Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China. 2. Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China. 3. Division of Pulmonary and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China. 4. Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Abstract
AIM: Interleukin-22 (IL-22) exhibits both proinflammatory and anti-inflammatory properties in various biological processes. In this study we explored the effects of exogenous recombinant IL-22 (rIL-22) on cigarette smoke (CS)-induced airway inflammation in mice. METHODS: Male C57BL/6 mice were divided into groups: (1) CS group exposed to tobacco smoke for 3 consecutive days, (2) rIL-22 group received rIL-22 (100 mg/kg, ip), and (3) CS plus rIL-22 group, received rIL-22 (100 mg/kg, ip) before the CS exposure. The airway resistance (Rn), lung morphology, inflammatory cells in the airways, and inflammatory cytokines and CXCR3 ligands in both bronchoalveolar lavage (BAL) fluids and lung tissues were analyzed. RESULTS: CS alone significantly elevated IL-22 level in the BAL fluid. Both CS and rIL-22 significantly augmented airway resistance, an influx of inflammatory cells into the airways and lung parenchyma, and significantly elevated levels of pro-inflammatory cytokines (TGFβ1 and IL-17A) and CXCR3 chemokines (particularly CXCL10) at the mRNA and/or protein levels. Furthermore, the effects of rIL-22 on airway resistance and inflammation were synergistic with those of CS, as demonstrated by a further increased Rn value, infiltration of greater numbers of inflammatory cells into the lung, higher levels of inflammatory cytokines and chemokines, and more severe pathological changes in CS plus rIL-22 group as compared to those in CS group. CONCLUSION: Exogenous rIL-22 exacerbates the airway inflammatory responses to CS exposure in part by inducing expression of several proinflammatory cytokines and CXCR3 ligands.
AIM: Interleukin-22 (IL-22) exhibits both proinflammatory and anti-inflammatory properties in various biological processes. In this study we explored the effects of exogenous recombinant IL-22 (rIL-22) on cigarette smoke (CS)-induced airway inflammation in mice. METHODS: Male C57BL/6 mice were divided into groups: (1) CS group exposed to tobacco smoke for 3 consecutive days, (2) rIL-22 group received rIL-22 (100 mg/kg, ip), and (3) CS plus rIL-22 group, received rIL-22 (100 mg/kg, ip) before the CS exposure. The airway resistance (Rn), lung morphology, inflammatory cells in the airways, and inflammatory cytokines and CXCR3 ligands in both bronchoalveolar lavage (BAL) fluids and lung tissues were analyzed. RESULTS:CS alone significantly elevated IL-22 level in the BAL fluid. Both CS and rIL-22 significantly augmented airway resistance, an influx of inflammatory cells into the airways and lung parenchyma, and significantly elevated levels of pro-inflammatory cytokines (TGFβ1 and IL-17A) and CXCR3 chemokines (particularly CXCL10) at the mRNA and/or protein levels. Furthermore, the effects of rIL-22 on airway resistance and inflammation were synergistic with those of CS, as demonstrated by a further increased Rn value, infiltration of greater numbers of inflammatory cells into the lung, higher levels of inflammatory cytokines and chemokines, and more severe pathological changes in CS plus rIL-22 group as compared to those in CS group. CONCLUSION: Exogenous rIL-22 exacerbates the airway inflammatory responses to CS exposure in part by inducing expression of several proinflammatory cytokines and CXCR3 ligands.
Authors: Spencer C Liang; Cheryl Nickerson-Nutter; Debra D Pittman; Yijun Carrier; Debra G Goodwin; Kathleen M Shields; Andre-Jean Lambert; Scott H Schelling; Quintus G Medley; Hak-Ling Ma; Mary Collins; Kyriaki Dunussi-Joannopoulos; Lynette A Fouser Journal: J Immunol Date: 2010-09-24 Impact factor: 5.422
Authors: Fanli Meng; Kai Wang; Tomonori Aoyama; Sergei I Grivennikov; YongHan Paik; David Scholten; Min Cong; Keiko Iwaisako; Xiao Liu; Mingjun Zhang; Christoph H Österreicher; Felix Stickel; Klaus Ley; David A Brenner; Tatiana Kisseleva Journal: Gastroenterology Date: 2012-06-08 Impact factor: 22.682
Authors: Kian Fan Chung; Sally E Wenzel; Jan L Brozek; Andrew Bush; Mario Castro; Peter J Sterk; Ian M Adcock; Eric D Bateman; Elisabeth H Bel; Eugene R Bleecker; Louis-Philippe Boulet; Christopher Brightling; Pascal Chanez; Sven-Erik Dahlen; Ratko Djukanovic; Urs Frey; Mina Gaga; Peter Gibson; Qutayba Hamid; Nizar N Jajour; Thais Mauad; Ronald L Sorkness; W Gerald Teague Journal: Eur Respir J Date: 2013-12-12 Impact factor: 16.671
Authors: Malcolm R Starkey; Maximilian W Plank; Paolo Casolari; Alberto Papi; Stelios Pavlidis; Yike Guo; Guy J M Cameron; Tatt Jhong Haw; Anthony Tam; Ma'en Obiedat; Chantal Donovan; Nicole G Hansbro; Duc H Nguyen; Prema Mono Nair; Richard Y Kim; Jay C Horvat; Gerard E Kaiko; Scott K Durum; Peter A Wark; Don D Sin; Gaetano Caramori; Ian M Adcock; Paul S Foster; Philip M Hansbro Journal: Eur Respir J Date: 2019-07-18 Impact factor: 16.671
Authors: Jessica L Barnes; Maximilian W Plank; Kelly Asquith; Steven Maltby; Lorena R Sabino; Gerard E Kaiko; Alyssa Lochrin; Jay C Horvat; Jemma R Mayall; Richard Y Kim; Philip M Hansbro; Simon Keely; Gabrielle T Belz; Hock L Tay; Paul S Foster Journal: Mucosal Immunol Date: 2021-06-03 Impact factor: 7.313